HUP0401925A3 - A2b adenosine receptor antagonists - Google Patents

A2b adenosine receptor antagonists

Info

Publication number
HUP0401925A3
HUP0401925A3 HU0401925A HUP0401925A HUP0401925A3 HU P0401925 A3 HUP0401925 A3 HU P0401925A3 HU 0401925 A HU0401925 A HU 0401925A HU P0401925 A HUP0401925 A HU P0401925A HU P0401925 A3 HUP0401925 A3 HU P0401925A3
Authority
HU
Hungary
Prior art keywords
receptor antagonists
adenosine receptor
adenosine
antagonists
receptor
Prior art date
Application number
HU0401925A
Other languages
English (en)
Original Assignee
Cv Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics filed Critical Cv Therapeutics
Publication of HUP0401925A2 publication Critical patent/HUP0401925A2/hu
Publication of HUP0401925A3 publication Critical patent/HUP0401925A3/hu
Publication of HU229504B1 publication Critical patent/HU229504B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0401925A 2001-11-09 2002-11-08 A2B-adenozinreceptor-antagonisták HU229504B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34822201P 2001-11-09 2001-11-09
US40140802P 2002-08-05 2002-08-05
PCT/US2002/035880 WO2003042214A2 (en) 2001-11-09 2002-11-08 A2b adenosine receptor antagonists

Publications (3)

Publication Number Publication Date
HUP0401925A2 HUP0401925A2 (hu) 2005-01-28
HUP0401925A3 true HUP0401925A3 (en) 2007-05-29
HU229504B1 HU229504B1 (hu) 2014-01-28

Family

ID=26995608

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401925A HU229504B1 (hu) 2001-11-09 2002-11-08 A2B-adenozinreceptor-antagonisták

Country Status (20)

Country Link
US (2) US6825349B2 (hu)
EP (1) EP1444233B1 (hu)
JP (1) JP4350517B2 (hu)
KR (1) KR100937620B1 (hu)
CN (1) CN100467469C (hu)
AT (1) ATE520694T1 (hu)
AU (1) AU2002359365B2 (hu)
CA (1) CA2466477C (hu)
CY (1) CY1112459T1 (hu)
DK (1) DK1444233T3 (hu)
HK (1) HK1071127A1 (hu)
HU (1) HU229504B1 (hu)
IL (2) IL161867A0 (hu)
MX (1) MXPA04004388A (hu)
NO (1) NO329692B1 (hu)
NZ (1) NZ532816A (hu)
PL (1) PL370207A1 (hu)
PT (1) PT1444233E (hu)
RU (1) RU2318824C2 (hu)
WO (1) WO2003042214A2 (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
EP1301187B1 (en) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7304070B2 (en) * 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
BR0302965A (pt) * 2002-02-01 2005-02-09 King Pharmaceuticals Res & Dev Composto e método de tratar doenças mediadas por receptores de adenosina a2b
WO2004011460A2 (en) 2002-07-24 2004-02-05 Qlt, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1524984A1 (en) * 2002-07-29 2005-04-27 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
AU2011224104B2 (en) * 2003-05-06 2012-06-28 Gilead Sciences, Inc. A2B adenosine receptor antagonists
MXPA05011860A (es) * 2003-05-06 2006-02-17 Cv Therapeutics Inc Derivados de xantina como antagonistas del receptor de adenosina a2b.
DK1658291T3 (da) * 2003-08-25 2013-10-28 Dogwood Pharmaceuticals Inc Substituerede 8-heteroaryl xanthiner
CN1890241A (zh) * 2003-10-31 2007-01-03 Cv医药有限公司 A2b腺苷受体拮抗剂
AU2011202523B2 (en) * 2003-11-21 2013-05-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20060058322A1 (en) * 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
CN101039677A (zh) * 2004-10-15 2007-09-19 Cv医药有限公司 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
KR20070083714A (ko) 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1989214B8 (en) 2006-02-03 2016-12-21 Gilead Sciences, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
CA2849661A1 (en) * 2006-03-17 2007-09-27 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US20080213165A1 (en) * 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
EP2066232A1 (en) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
MX2010006378A (es) 2007-12-11 2010-09-07 Schering Corp Moduladores de gamma secretasa.
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
WO2010009194A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
MX2012015112A (es) * 2010-06-30 2013-05-28 Gilead Sciences Inc Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CA2810625C (en) * 2010-09-13 2018-01-23 Advinus Therapeutics Private Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
EP2678338B1 (en) 2011-02-25 2015-09-09 Novartis AG Pyrazolo[1,5-a]pyridines as trk inhibitors
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2013062762A1 (en) * 2011-10-27 2013-05-02 Proteotech Inc Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
EP2797893B1 (en) * 2011-12-27 2017-11-22 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
SI2970303T1 (sl) 2013-03-15 2017-08-31 Hydra Biosciences, Inc. Substituirani ksantini in njihove metode uporabe
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
CN104744469A (zh) * 2014-10-31 2015-07-01 合肥平光制药有限公司 一种茶碱的制备方法
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
EP3414319A4 (en) 2016-02-10 2019-08-28 Wake Forest University Health Sciences HEPATIC FIBROSIS MODEL SYSTEM AND METHOD FOR MANUFACTURING AND USING SAME
BR112020018158A2 (pt) 2018-03-05 2021-02-02 Teon Therapeutics, Inc. antagonistas de receptor de adenosina e usos dos mesmos
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
KR20210061202A (ko) 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
KR20210076693A (ko) 2019-12-16 2021-06-24 일동제약(주) 질소를 포함하는 헤테로고리로 치환된 축합 피리미딘 유도체 및 그의 의약 용도
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4452788A (en) 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1999042092A2 (en) 1998-02-20 1999-08-26 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
DE29902571U1 (de) 1998-05-19 2000-03-23 Papst Motoren Gmbh & Co Kg Elektronisch kommutierter Motor
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
EP1084710B1 (en) 1998-06-01 2006-10-18 Astellas Pharma Inc. Adenosine a1 antagonists for male sterility
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6437154B1 (en) 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists

Also Published As

Publication number Publication date
CA2466477C (en) 2012-10-02
AU2002359365B2 (en) 2008-07-10
HUP0401925A2 (hu) 2005-01-28
CN1585769A (zh) 2005-02-23
JP2005509036A (ja) 2005-04-07
US7105665B2 (en) 2006-09-12
US6825349B2 (en) 2004-11-30
NO329692B1 (no) 2010-12-06
WO2003042214A2 (en) 2003-05-22
WO2003042214A3 (en) 2004-03-04
KR100937620B1 (ko) 2010-01-20
ATE520694T1 (de) 2011-09-15
RU2318824C2 (ru) 2008-03-10
US20050038045A1 (en) 2005-02-17
DK1444233T3 (da) 2011-10-17
NZ532816A (en) 2005-11-25
KR20050044361A (ko) 2005-05-12
RU2004114210A (ru) 2005-09-10
NO20042378L (no) 2004-07-20
PT1444233E (pt) 2011-09-29
CY1112459T1 (el) 2015-12-09
EP1444233A2 (en) 2004-08-11
JP4350517B2 (ja) 2009-10-21
CN100467469C (zh) 2009-03-11
HK1071127A1 (en) 2005-07-08
AU2002359365A2 (en) 2003-05-26
HU229504B1 (hu) 2014-01-28
IL161867A (en) 2015-01-29
IL161867A0 (en) 2005-11-20
CA2466477A1 (en) 2003-05-22
MXPA04004388A (es) 2005-05-16
PL370207A1 (en) 2005-05-16
US20030139428A1 (en) 2003-07-24
EP1444233B1 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
HUP0401925A3 (en) A2b adenosine receptor antagonists
AU6808901A (en) Adenosine a2a receptor antagonists
HK1063780A1 (en) Adenosine a2a receptor antagonists
IL161572A0 (en) Adenosine a2a receptor antagonists
IL175759A0 (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
IL155712A0 (en) Aminothiazoles and their use as adenosine receptor antagonists
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
IL158214A0 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
PL373953A1 (en) 7-amino-benzothiazole derivatives as adenosine receptor ligands
HK1049835A1 (en) Selective antagonists of a2b adenosine receptors a2b.
EP1370676A4 (en) CYTOKIN RECEPTOR FROM MOUSE
HUP0303533A3 (en) Adenosine a1 agonist adenosine derivatives
HRP20040672A2 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU2002359524A8 (en) P2x7 receptor antagonists
HK1047750A1 (zh) 趨化因子受體拮抗劑
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
IL156087A0 (en) Histamine receptor antagonists
PL370367A1 (en) Ccr-3 receptor antagonists v
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
AU2002367281A8 (en) Isolated cytokine receptor licr-2
IL158063A0 (en) Crf receptor antagonists
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
AU2002320199A1 (en) Purine derivatives as a2b adenosine receptor antagonists
GB0125183D0 (en) Receptor

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: GILEAD SCIENCES, INC., US

Free format text: FORMER OWNER(S): CV THERAPEUTICS, INC., US

MM4A Lapse of definitive patent protection due to non-payment of fees